Company intelligence / Profile preview
Newsoara Biopharma
Shanghai, Chinanewsoara.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting Phase 1b/2 trials for Olvi-Vec in advanced small cell lung cancer with promising preliminary results showing anti-tumor responses in heavily pre-treated patients. Also received NMPA clearance in China for Phase 3 clinical trial of LB1148 to accelerate return of bowel function following abdominal surgery. Phase 2 studies for HPP737 in psoriasis, COPD, and atopic dermatitis are ongoing in China.
- Therapeutic areas
- PulmonologyMetabolic DisordersImmunologyDermatologyOncology
- Modalities
- Small moleculesoncolytic viruses
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Genelux CorporationPalisade BioZenith Epigenetics Ltd.VTV Therapeutics
Beyond the preview
Go deeper on Newsoara Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Newsoara Biopharma.